Estradiol Valerate CAS 979-32-8

Product Description:

Product Name: Estradiol valerate CAS NO: 979-32-8

Synonyms:

delestro-gen;

delestro-gen4x;

estradiol17-beta-valerate;estradiolvalerianate;

Chemical & Physical Properties:

Appearance: Off-White Solid

Assay :≥99.0%

Density: 1.13g/cm3

Boiling Point: 486.2℃ at 760mmHg

Melting Point: 144℃

Flash Point: 191.1℃

Refractive Index: 1.567

Vapour Pressure: 0.0±1.3 mmHg at 25℃

Storage Temp.: Sealed in dry,Room Temperature

Solubility: Practically insoluble in water, soluble in alcohol.

Safety Information:

RTECS: KG5793000

Safety Statements: S53-S45

WGK Germany: 3

Risk Statements: R60; R61

Hazard Code: T

Estradiol valerate (EV, E2V) (INN, USAN, JAN) (brand names Altadiol, Deladiol, Delestro-gen, Estraval, Lastrogen, Progynova, Valergen, many others), or oestradiol valerate (BAN), is a synthetic ester, specifically the 17-pentanoyl ester, of the natural estro-gen, 17β-estradiol. It was first introduced, as Delestro-gen by Squibb in the United States, in 1954, and along with estradiol benzoate (1936) and estradiol cypionate (1952), has since become one of the most widely used esters of estradiol.

Upon ingestion, regardless of the route of administration, estradiol valerate behaves as a prodrug, being cleaved by esterases in blood plasma and the liver into 17β-estradiol and valeric acid. However, compared to estradiol itself, estradiol valerate is absorbed more slowly and possesses a longer duration, especially when given in an oil solution via intramuscular injection (in which it acts as a depot). As a result, it can be administered less frequently.

A single intramuscular injection of 4mg estradiol valerate results in maximal plasma levels of estradiol of about 390 pg/mL within three days of administration, with levels declining to 100 pg/mL by 12–13 days. A study of high-dose combined administration of 40mg estradiol valerate and 250mg hydroxyprogesterone caproate in women once weekly for six months (described as a "pseudopregnancy" regimen) found that serum levels of estradiol increased from 27.8–34.8 pg/mL to 3028–3226 pg/mL after three months and to 2491–2552 pg/mL after six months of treatment.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.